Spinifex Announces Positive Phase 2 Results for EMA401 in Postherpetic Neuralgia
Trial Meets Primary Endpoint: Reduction in Pain
29-Aug-2012 -
Spinifex Pharmaceuticals announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all ...
herpes zoster
phase II studies